Document registry — page 21
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Record of documents ratified in the 2025 Q3 assessment cycle.
18 Sep 2025 -
Growth-hormone C-terminal fragment analogue. The proposed mechanism is stimulation of lipolysis and inhibition of lipogenesis in adipose tissue without the growth-hormone-receptor-mediated…
Very low17 Sep 2025 -
Consultation on the draft monograph for danuglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist whose development programme was discontinued. The draft…
16 Sep 2025 -
Consultation on the draft monograph for DSIP, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
14 Sep 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Sep 2025 -
Assessment of appearance, cake integrity and reconstitution behaviour
High13 Sep 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Sep 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity and type 2 diabetes over 72 weeks. The Institute holds no reported primary result…
09 Sep 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Sep 2025 -
Consultation on the draft monograph for Liraglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
06 Sep 2025 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the effect of Liraglutide compared with the comparator used in its contributing trials on…
Moderate04 Sep 2025 -
A reproductive-endocrine disorder defined by combinations of ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology.
01 Sep 2025 -
Persistently reduced sexual desire or impaired erectile function causing distress, assessed by validated instruments.
31 Aug 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Aug 2025 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes randomising 9,650 participants over median 47.5…
Moderate25 Aug 2025 -
Development and validation of a stability-indicating method for peptide preparations
High21 Aug 2025 -
Mitochondrial-derived 16-residue peptide. MOTS-c is described as a mitochondrial-encoded regulator of metabolic homeostasis that acts through the folate one-carbon cycle to raise…
Very low20 Aug 2025 -
In the population defined for obesity and overweight in adults, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate18 Aug 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cognition randomising 194 participants over 96 weeks. Primary result: No significant…
Moderate16 Aug 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide, oral maintained across the full duration of the contributing trials?
High06 Aug 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the…
High04 Aug 2025 -
In the population defined for obesity and overweight in adults, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High01 Aug 2025 -
Identification and quantification of counter-ions in synthetic peptide salts
High31 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over as stated in the parent protocol. The Institute holds…
Very low30 Jul 2025 -
Insufficient endogenous growth-hormone secretion, or the pharmacological stimulation of the growth-hormone axis, assessed here principally through provocative testing…
29 Jul 2025 -
Photostability assessment of light-sensitive peptides
High27 Jul 2025 -
What randomised evidence supports mitochondria-targeted peptides in primary mitochondrial disease and in age-related functional decline?
Low25 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low25 Jul 2025 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with Thymosin beta-4 compared…
Low24 Jul 2025 -
Loss of skeletal muscle mass and function, considered here principally as a consequence of rapid weight reduction under incretin therapy.
24 Jul 2025 -
Sub-visible particulate matter in reconstituted peptide solutions
High24 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
17 Jul 2025 -
Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an efficacy and tolerability profile comparable with an injectable presentation?
Moderate16 Jul 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Survodutide compared with its…
Moderate15 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Jul 2025 -
Peptides, SARMs, injectable oils and raw materials.
11 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity randomising 610 participants over 48 weeks. Primary result: Mean change −14.0 % at 6…
Moderate09 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Jul 2025 -
Consultation on the second version of the tirzepatide monograph, which incorporates the obesity evidence from SURMOUNT-1, reported in the New England Journal of Medicine…
02 Jul 2025
page 21 of 41